ID
44620
Description
An open-label, multicenter, randomized, comparative, phase III study to evaluate the efficacy and safety of rituximab plus fludarabine and cyclophosphamide (FCR) versus fludarabine and cyclophosphamide alone (FC) in previously treated patients with CD20 positive B-cell chronic lymphocytic leukemia (CLL). NCT00090051
Keywords
Versions (3)
- 9/30/15 9/30/15 -
- 10/28/15 10/28/15 -
- 9/27/21 9/27/21 -
Uploaded on
September 27, 2021
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
CLL Completion BO17072 NCT00090051
Treatment phase completion Chronic Lymphocytic Leukemia BO17072 NCT00090051
Description
Treatment phase completion
Description
Date of last dosing
Data type
date
Measurement units
- dd/mm/yy
Alias
- UMLS CUI [1]
- C3173975
Description
Study completion
Data type
boolean
Alias
- UMLS CUI [1]
- C2826674
Description
Reason for no completion
Data type
integer
Alias
- UMLS CUI [1]
- C0205197
Description
Specify violation of selection criteria
Data type
text
Alias
- UMLS CUI [1]
- C1709750
Description
Specify other protocol violation
Data type
text
Alias
- UMLS CUI [1]
- C1709750
Description
Specify other reason
Data type
text
Alias
- UMLS CUI [1]
- C3840932
Description
Additional observations
Description
Please record any significant clinical observations related to the trial drug, not reported in other parts of the CRF, including observations toward a possible therapeutic activity outside the studied indication and potential drug interactions.
Data type
text
Alias
- UMLS CUI [1]
- C0560166